Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EBP-A.muc-LBP2
- Development stage
- Preclinical
- Lead developer
- Enterobiome
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
EBP-A.muc-LBP2 is an investigational live biotherapeutic product (LBP) developed by Enterobiome, a South Korean biotechnology company. It is composed of the gut commensal bacterium *Akkermansia muciniphila* and is specifically designed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The mechanism of action involves the modulation of host metabolism and the reinforcement of the intestinal barrier, which in turn reduces systemic and liver-specific inflammation associated with fatty liver disease. Currently in the IND-enabling stage, the program is undergoing preclinical efficacy and toxicology studies with a target for clinical entry around 2027.
- Other names
- Enterobiome-A.muciniphila-LBP (MASH)EBP A. muciniphila LBP2EB-AMDK19EB-AMDK-19EB-AMDK 19
Beyond the preview
Go deeper on EBP-A.muc-LBP2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EBP-A.muc-LBP2.